➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
McKesson
Express Scripts
Harvard Business School
Medtronic

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022249


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 022249 describes TREANDA, which is a drug marketed by Cephalon and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug and two Paragraph IV challenges. Additional details are available on the TREANDA profile page.

The generic ingredient in TREANDA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
Summary for 022249
Tradename:TREANDA
Applicant:Cephalon
Ingredient:bendamustine hydrochloride
Patents:9
Formulation / Manufacturing:see details
Pharmacology for NDA: 022249
Mechanism of ActionAlkylating Activity
Medical Subject Heading (MeSH) Categories for 022249
Suppliers and Packaging for NDA: 022249
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TREANDA bendamustine hydrochloride POWDER;IV (INFUSION) 022249 NDA Cephalon, Inc. 63459-390 63459-390-08 1 VIAL, SINGLE-DOSE in 1 CARTON (63459-390-08) > 5 mL in 1 VIAL, SINGLE-DOSE
TREANDA bendamustine hydrochloride SOLUTION;IV (INFUSION) 022249 NDA Cephalon, Inc. 63459-390 63459-390-08 1 VIAL, SINGLE-DOSE in 1 CARTON (63459-390-08) > 5 mL in 1 VIAL, SINGLE-DOSE
Paragraph IV (Patent) Challenges for 022249
Tradename Dosage Ingredient NDA Submissiondate
TREANDA POWDER;IV (INFUSION) bendamustine hydrochloride 022249 2014-06-19
TREANDA SOLUTION;IV (INFUSION) bendamustine hydrochloride 022249 2014-06-19
TREANDA SOLUTION;IV (INFUSION) bendamustine hydrochloride 022249 2013-06-04
TREANDA POWDER;IV (INFUSION) bendamustine hydrochloride 022249 2013-06-04

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;IV (INFUSION)Strength100MG/VIAL
Approval Date:Mar 20, 2008TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Apr 26, 2031Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Sep 26, 2029Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Jul 12, 2026Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Boehringer Ingelheim
Dow
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.